Angiotensin II

Overview

Angiotensin II (Ang II) is an octapeptide hormone that serves as the primary effector of the renin-angiotensin-aldosterone system (RAAS), one of the most important physiological systems regulating blood pressure, fluid balance, and electrolyte homeostasis. It is among the most potent vasoconstrictors known, and its signaling pathways influence virtually every organ system in the body.

The clinical significance of angiotensin II cannot be overstated. Drugs that block its production (ACE inhibitors) or its receptor (angiotensin receptor blockers, ARBs) are among the most widely prescribed medications worldwide, used by hundreds of millions of people for hypertension, heart failure, and kidney protection. Understanding Ang II is essential for comprehending cardiovascular pharmacology and the broader landscape of peptide-based signaling.

Structure and Properties

Amino Acid Sequence

Asp-Arg-Val-Tyr-Ile-His-Pro-Phe

• Molecular weight: 1,046.19 g/mol
• Molecular formula: C50H71N13O12
• Length: 8 amino acids (octapeptide)
• Half-life: Approximately 1-2 minutes in circulation (rapidly degraded by angiotensinases)

Biosynthesis: The RAAS Cascade

Angiotensin II is not synthesized directly but is produced through a two-step enzymatic cascade:

Step 1: Renin The juxtaglomerular cells of the kidney release renin in response to:

• Decreased renal perfusion pressure
• Decreased sodium delivery to the macula densa
• Sympathetic nervous system activation (beta-1 receptor stimulation)

Renin cleaves angiotensinogen (a 453-amino-acid protein produced by the liver) to produce angiotensin I, a biologically inactive decapeptide.

Step 2: Angiotensin-Converting Enzyme (ACE) ACE, primarily located on the surface of pulmonary endothelial cells (but also present in other vascular beds and tissues), cleaves the C-terminal dipeptide (His-Leu) from angiotensin I, producing the active octapeptide angiotensin II.

ACE also degrades bradykinin, a vasodilator — this dual action means ACE inhibition both reduces vasoconstriction (less Ang II) and enhances vasodilation (more bradykinin).

Receptors

Angiotensin II acts through two primary receptor subtypes:

AT1 Receptor (Angiotensin Type 1)

The principal mediator of most known cardiovascular effects of Ang II:

• Vasoconstriction — Contraction of vascular smooth muscle, raising blood pressure
• Aldosterone secretion — Stimulates the adrenal cortex to release aldosterone, promoting sodium and water retention
• Sympathetic activation — Enhances norepinephrine release from sympathetic nerve terminals
• Cardiac hypertrophy — Promotes cardiomyocyte growth and fibrosis
• Renal effects — Constricts efferent arterioles, maintains glomerular filtration pressure but increases intraglomerular pressure
• Thirst and ADH release — Acts on hypothalamic nuclei to stimulate thirst and vasopressin secretion
• Pro-inflammatory and pro-fibrotic — Activates NF-kB, increases ROS production, promotes tissue remodeling

AT1 receptors are found in blood vessels, heart, kidneys, adrenal glands, brain, liver, and many other tissues. The AT1 receptor is a G-protein coupled receptor central to blood pressure regulation.

AT2 Receptor (Angiotensin Type 2)

Generally opposes AT1 effects:

• Vasodilation — Via nitric oxide and bradykinin pathways
• Anti-proliferative — Inhibits cell growth and promotes apoptosis
• Anti-inflammatory — Reduces tissue inflammation
• Neuroprotective — Evidence of neuronal protective effects
• Tissue repair — May promote regenerative processes

AT2 receptors are highly expressed during fetal development and decline in adulthood, though they are re-expressed under pathological conditions (tissue injury, heart failure). The balance between AT1 and AT2 signaling determines the net effect of angiotensin II on any given tissue.

Pharmacological Targeting of the RAAS

ACE Inhibitors

These drugs block the conversion of angiotensin I to angiotensin II:

Drug	Notes
Enalapril	First orally active ACE inhibitor (prodrug)
Lisinopril	No hepatic conversion required; renal excretion
Ramipril	Demonstrated cardiovascular protection in HOPE trial
Captopril	First ACE inhibitor; short-acting; thiol group

Clinical applications: Hypertension, heart failure, post-MI remodeling prevention, diabetic nephropathy, chronic kidney disease

Key side effect: Dry cough (10-20% of patients) due to bradykinin accumulation in the airways. This side effect led to the development of ARBs.

Angiotensin Receptor Blockers (ARBs)

These drugs selectively block the AT1 receptor, preventing Ang II from exerting its vasoconstrictive and aldosterone-stimulating effects:

Drug	Notes
Losartan	First approved ARB; active metabolite EXP-3174
Valsartan	Widely used; VALIANT trial data
Telmisartan	Longest half-life; PPAR-gamma activation
Candesartan	High AT1 receptor affinity
Olmesartan	Potent; ROADMAP trial for diabetic nephropathy

Advantages over ACE inhibitors: No cough (bradykinin is not affected); may allow AT2 receptor activation by unblocked Ang II (potentially beneficial)

Direct Renin Inhibitors

Aliskiren blocks the RAAS at its inception by inhibiting renin. Despite theoretical advantages, clinical outcomes trials have not shown superiority over ACE inhibitors or ARBs, and combination with these agents was associated with adverse events.

Angiotensin II as a Drug

In a notable reversal, synthetic angiotensin II itself (Giapreza) received FDA approval in 2017 for the treatment of refractory hypotension in septic shock — a condition where vasodilatory shock produces dangerously low blood pressure unresponsive to standard vasopressors. This represents one of the few instances where a vasoconstrictor peptide is administered therapeutically.

The Broader Angiotensin Peptide Family

Angiotensin II is not the only bioactive product of the RAAS. Several metabolites have distinct biological activities:

Angiotensin-(1-7)

Produced from Ang II by ACE2 (the same enzyme that serves as the SARS-CoV-2 receptor). Acts through the Mas receptor to produce effects that oppose Ang II/AT1:

• Vasodilation
• Anti-inflammatory effects
• Anti-fibrotic activity
• Cardioprotective and renoprotective effects

The ACE2/Ang-(1-7)/Mas axis is considered a counter-regulatory arm of the renin-angiotensin system that balances the pro-hypertensive effects of the classical ACE/Ang II/AT1 axis.

Angiotensin IV

The hexapeptide fragment Ang II(3-8), produced by aminopeptidase cleavage. Binds to the AT4 receptor (insulin-regulated aminopeptidase, IRAP). Research has linked Ang IV to cognitive enhancement and memory improvement. Dihexa, a synthetic analog of Ang IV, was developed based on this cognitive-enhancing activity and demonstrates extraordinary potency in preclinical cognitive models.

Angiotensin III

The heptapeptide Ang II(2-8). Active at AT1 and AT2 receptors with a primary role in stimulating aldosterone secretion.

Pathological Roles of Angiotensin II

Hypertension

Excessive RAAS activation is a major contributor to essential hypertension. Ang II drives elevated blood pressure through vasoconstriction, sodium retention, sympathetic activation, and vascular remodeling.

Heart Failure

Ang II contributes to the progression of heart failure through:

• Cardiac hypertrophy and fibrosis
• Increased afterload (vasoconstriction)
• Sodium and water retention (volume overload)
• Neurohormonal activation

RAAS blockade is a cornerstone of heart failure therapy, with mortality reduction demonstrated in numerous large clinical trials.

Chronic Kidney Disease

Intraglomerular hypertension driven by Ang II accelerates kidney damage. ACE inhibitors and ARBs slow the progression of diabetic and non-diabetic kidney disease, primarily by reducing intraglomerular pressure.

Vascular Inflammation and Atherosclerosis

Ang II promotes vascular inflammation and atherosclerosis through:

• ROS generation via NADPH oxidase activation
• NF-kB-mediated inflammatory gene expression
• Endothelial dysfunction
• Monocyte recruitment and macrophage activation
• Smooth muscle cell proliferation

These effects contribute to the initiation and progression of atherosclerotic plaques.

Dosing Protocols

The following dosing information reflects FDA-approved clinical guidelines for synthetic angiotensin II (Giapreza), approved in 2017. Always consult a qualified healthcare professional.

Indication	Starting Dose	Titration	Route	Maximum
Refractory hypotension (vasodilatory shock)	20 ng/kg/min	Titrate by 15 ng/kg/min every 5 min as needed	Continuous IV infusion	80 ng/kg/min (initial); up to 200 ng/kg/min

Administration notes: Used in ICU settings for adults with septic or other distributive shock who remain hypotensive despite adequate fluid resuscitation and vasopressor therapy. Requires continuous hemodynamic monitoring. Titrate to target mean arterial pressure. Thrombotic events have been reported; concurrent VTE prophylaxis is recommended. As an endogenous vasoactive peptide, angiotensin II is primarily studied as a component of the renin-angiotensin-aldosterone system rather than as an exogenous therapeutic in most contexts.

Research Significance

Angiotensin II research illustrates several fundamental principles in peptide biology:

• Cascade signaling: A single peptide (angiotensinogen) gives rise to multiple bioactive fragments via post-translational modification with distinct and sometimes opposing activities
• Receptor subtypes: The same ligand can produce opposite effects depending on which receptor subtype it activates (AT1 vs. AT2)
• Clinical translation success: RAAS-targeting drugs represent one of the greatest successes in translating peptide biology into clinical medicine, with billions of prescriptions written annually
• Metabolite activity: Peptide degradation products (Ang-(1-7), Ang IV) are not merely inactive waste but carry their own biological activities — a principle relevant to understanding other peptide systems
• Therapeutic duality: The same molecule (Ang II) can be both pathological (hypertension) and therapeutic (septic shock), depending entirely on clinical context